Stuart A Scott

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/344649/publications.pdf

Version: 2024-02-01

114 papers	6,750 citations	66343 42 h-index	69250 77 g-index
116 all docs	116 docs citations	116 times ranked	9135 citing authors

#	Article	IF	Citations
1	Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clinical Pharmacology and Therapeutics, 2022, 112, 959-967.	4.7	166
2	Clinical pharmacogenomic testing and reporting: A technical standard of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2022, 24, 759-768.	2.4	16
3	Effects of Testing and Disclosing Ancestry-Specific Genetic Risk for Kidney Failure on Patients and Health Care Professionals. JAMA Network Open, 2022, 5, e221048.	5.9	9
4	PharmVar GeneFocus: CYP2C19. Clinical Pharmacology and Therapeutics, 2021, 109, 352-366.	4.7	72
5	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clinical Pharmacology and Therapeutics, 2021, 109, 1417-1423.	4.7	157
6	Development and Analytical Validation of a 29 Gene Clinical Pharmacogenetic Genotyping Panel: Multiâ€Ethnic Allele and Copy Number Variant Detection. Clinical and Translational Science, 2021, 14, 204-213.	3.1	16
7	Multiâ€site Investigation of Genetic Determinants of Warfarin Dose Variability in Latinos. Clinical and Translational Science, 2021, 14, 268-276.	3.1	7
8	Pharmacogenomic Determinants of Interindividual Drug Response Variability: From Discovery to Implementation. Genes, 2021, 12, 393.	2.4	1
9	Pharmacogenomic education among genetic counseling training programs in North America. Journal of Genetic Counseling, 2021, 30, 1500-1508.	1.6	18
10	Multi-Institutional Implementation of Clinical Decision Support for APOL1, NAT2, and YEATS4 Genotyping in Antihypertensive Management. Journal of Personalized Medicine, 2021, 11, 480.	2.5	6
11	Deletion of ERF and CIC causes abnormal skull morphology and global developmental delay. Journal of Physical Education and Sports Management, 2021, 7, a005991.	1.2	3
12	PharmVar GeneFocus: CYP2C9. Clinical Pharmacology and Therapeutics, 2021, 110, 662-676.	4.7	34
13	Pharmacogenomic polygenic risk score for clopidogrel responsiveness among Caribbean Hispanics: A candidate gene approach. Clinical and Translational Science, 2021, 14, 2254-2266.	3.1	15
14	Novel Pharmacogenomic Locus Implicated in Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema. Journal of the American College of Cardiology, 2021, 78, 710-712.	2.8	2
15	Recommendations for Clinical CYP2D6 Genotyping Allele Selection. Journal of Molecular Diagnostics, 2021, 23, 1047-1064.	2.8	73
16	Machine Learning for Prediction of Stable Warfarin Dose in US Latinos and Latin Americans. Frontiers in Pharmacology, 2021, 12, 749786.	3.5	10
17	A Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy. Clinical Pharmacology and Therapeutics, 2020, 107, 50-52.	4.7	22
18	Standardizing <scp>CYP</scp>2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clinical and Translational Science, 2020, 13, 116-124.	3.1	353

#	Article	IF	Citations
19	Genetic Factors Influencing Warfarin Dose in Blackâ€African Patients: A Systematic Review and Metaâ€Analysis. Clinical Pharmacology and Therapeutics, 2020, 107, 1420-1433.	4.7	40
20	VarCover. Journal of Molecular Diagnostics, 2020, 22, 123-131.	2.8	2
21	Phased Haplotype Resolution of the SLC6A4 Promoter Using Long-Read Single Molecule Real-Time (SMRT) Sequencing. Genes, 2020, 11, 1333.	2.4	5
22	Implementing a pharmacogenetic-driven algorithm to guide dual antiplatelet therapy (DAPT) in Caribbean Hispanics: protocol for a non-randomised clinical trial. BMJ Open, 2020, 10, e038936.	1.9	10
23	Digital Health Applications for Pharmacogenetic Clinical Trials. Genes, 2020, 11, 1261.	2.4	6
24	Recommendations for Clinical Warfarin Genotyping Allele Selection. Journal of Molecular Diagnostics, 2020, 22, 847-859.	2.8	39
25	Haploinsufficiency of the basic helixâ€“loopâ€“helix transcription factor HAND2 causes congenital heart defects. American Journal of Medical Genetics, Part A, 2020, 182, 1263-1267.	1.2	11
26	Clinical Pharmacogenetic Testing and the Posttest Counseling Conundrum. Clinical Pharmacology and Therapeutics, 2020, 108, 924-928.	4.7	5
27	Knowledge and attitudes on pharmacogenetics among pediatricians. Journal of Human Genetics, 2020, 65, 437-444.	2.3	52
28	Familial inheritance of the 3q29 microdeletion syndrome: case report and review. BMC Medical Genomics, 2019, 12, 51.	1.5	7
29	Structural variation at the CYP2C locus: Characterization of deletion and duplication alleles. Human Mutation, 2019, 40, e37-e51.	2.5	15
30	Characterization of Reference Materials for Genetic Testing of CYP2D6 Alleles. Journal of Molecular Diagnostics, 2019, 21, 1034-1052.	2.8	55
31	Pharmacogenomics in Latin American Populations. , 2019, , 329-368.		1
32	Reactive, Point-of-Care, Preemptive, and Direct-to-Consumer Pharmacogenomics Testing. , 2019, , 369-384.		3
33	Prenatal cytogenomic identification and molecular refinement of compound heterozygous STRC deletion breakpoints. Molecular Genetics & Genomic Medicine, 2019, 7, e806.	1.2	4
34	Interpreting and Implementing Clinical Pharmacogenetic Tests: Perspectives From Service Providers. Clinical Pharmacology and Therapeutics, 2019, 106, 298-301.	4.7	6
35	Recommendations for Clinical CYP2C9 Genotyping Allele Selection. Journal of Molecular Diagnostics, 2019, 21, 746-755.	2.8	84
36	Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing. Genetics in Medicine, 2019, 21, 2255-2263.	2.4	53

#	Article	IF	Citations
37	Pharmacogene Variation Consortium Gene Introduction: <scp>NUDT15</scp>. Clinical Pharmacology and Therapeutics, 2019, 105, 1091-1094.	4.7	45
38	Essential Characteristics of Pharmacogenomics Study Publications. Clinical Pharmacology and Therapeutics, 2019, 105, 86-91.	4.7	9
39	Integrated CYP2D6 interrogation for multiethnic copy number and tandem allele detection. Pharmacogenomics, 2019, 20, 9-20.	1.3	9
40	Effect of <scp>CYP</scp>4F2,<scp>VKORC</scp>1, and <scp>CYP</scp>2C9 in Influencing Coumarin Dose: A Singleâ€Patient Data Metaâ€Analysis in More Than 15,000 Individuals. Clinical Pharmacology and Therapeutics, 2019, 105, 1477-1491.	4.7	23
41	Development of a Genomic Data Flow Framework: Results of a Survey Administered to NIH-NHGRI IGNITE and eMERGE Consortia Participants. AMIA ... Annual Symposium proceedings, 2019, 2019, 363-370.	0.2	1
42	Recommendations for Clinical CYP2C19 Genotyping Allele Selection. Journal of Molecular Diagnostics, 2018, 20, 269-276.	2.8	131
43	Effect of cilostazol on platelet reactivity among patients with peripheral artery disease on clopidogrel therapy. Drug Metabolism and Personalized Therapy, 2018, 33, 49-55.	0.6	6
44	Cytogenomic identification and long-read single molecule real-time (SMRT) sequencing of a Bardetâ€“Biedl Syndrome 9 (BBS9) deletion. Npj Genomic Medicine, 2018, 3, 3.	3.8	97
45	Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotypeâ€Guided Antiplatelet Therapy. Clinical Pharmacology and Therapeutics, 2018, 104, 664-674.	4.7	94
46	2042 CYP2C19*2 and PON1 Q192R polymorphisms are associated with platelet reactivity to clopidogrel in Puerto Rican Hispanics with cardiovascular disease. Journal of Clinical and Translational Science, 2018, 2, 8-8.	0.6	2
47	Multi-ethnicSULT1A1copy number profiling with multiplex ligation-dependent probe amplification. Pharmacogenomics, 2018, 19, 761-770.	1.3	9
48	Pharmacogenetic association study on clopidogrel response in Puerto Rican Hispanics with cardiovascular disease: a novel characterization of a Caribbean population. Pharmacogenomics and Personalized Medicine, 2018, Volume 11, 95-106.	0.7	7
49	Multi-ethnic genome-wide association study for atrial fibrillation. Nature Genetics, 2018, 50, 1225-1233.	21.4	552
50	Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation. Nature Genetics, 2017, 49, 946-952.	21.4	279
51	Concordance between Research Sequencing and Clinical Pharmacogenetic Genotyping in the eMERGE-PGx Study. Journal of Molecular Diagnostics, 2017, 19, 561-566.	2.8	18
52	Sequencing the CYP2D6 gene: from variant allele discovery to clinical pharmacogenetic testing. Pharmacogenomics, 2017, 18, 673-685.	1.3	105
53	Apolipoprotein L1 VariantsÂand Blood Pressure Traits inÂAfrican Americans. Journal of the American College of Cardiology, 2017, 69, 1564-1574.	2.8	46
54	Maternal uniparental disomy of chromosome 15 and concomitant STRC and CATSPER2 deletionâ€mediated deafnessâ€infertility syndrome. American Journal of Medical Genetics, Part A, 2017, 173, 1436-1439.	1.2	6

#	Article	IF	Citations
55	Chromosomal Microarray Detection of Constitutional Copy Number Variation Using Saliva DNA. Journal of Molecular Diagnostics, 2017, 19, 397-403.	2.8	10
56	DNA Methylation Profiling Using Long-Read Single Molecule Real-Time Bisulfite Sequencing (SMRT-BS). Methods in Molecular Biology, 2017, 1654, 125-134.	0.9	21
57	Institutional profile: translational pharmacogenomics at the Icahn School of Medicine at Mount Sinai. Pharmacogenomics, 2017, 18, 1381-1386.	1.3	20
58	Clinical determinants of clopidogrel responsiveness in a heterogeneous cohort of Puerto Rican Hispanics. Therapeutic Advances in Cardiovascular Disease, 2017, 11, 235-241.	2.1	7
59	Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genetics in Medicine, 2017, 19, 215-223.	2.4	410
60	Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study. Frontiers in Pharmacology, 2017, 8, 347.	3.5	18
61	Modeling susceptibility to drug-induced long QT with a panel of subject-specific induced pluripotent stem cells. ELife, 2017, 6, .	6.0	82
62	Long-Read Single Molecule Real-Time Full Gene Sequencing of Cytochrome P450-2D6. Human Mutation, 2016, 37, 315-323.	2.5	86
63	Implementing Algorithmâ€Guided Warfarin Dosing in an Ethnically Diverse Patient Population Using Electronic Health Records and Preemptive CYP2C9 and VKORC1 Genetic Testing. Clinical Pharmacology and Therapeutics, 2016, 100, 427-430.	4.7	11
64	A de novo 2.78-Mb duplication on chromosome 21q22.11 implicates candidate genes in the partial trisomy 21 phenotype. Npj Genomic Medicine, 2016, 1, .	3.8	9
65	Analytical Validation of a Personalized Medicine APOL1 Genotyping Assay for Nondiabetic Chronic Kidney Disease Risk Assessment. Journal of Molecular Diagnostics, 2016, 18, 260-266.	2.8	10
66	Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes. Journal of Molecular Diagnostics, 2016, 18, 109-123.	2.8	116
67	Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach. Lancet Psychiatry,the, 2016, 3, 350-357.	7.4	107
68	Association of Arrhythmia-Related Genetic Variants With Phenotypes Documented in Electronic Medical Records. JAMA - Journal of the American Medical Association, 2016, 315, 47.	7.4	148
69	The pharmacogenetic control of antiplatelet response: candidate genes andCYP2C19. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1599-1617.	3.3	22
70	Quantitative and multiplexed DNA methylation analysis using long-read single-molecule real-time bisulfite sequencing (SMRT-BS). BMC Genomics, 2015, 16, 350.	2.8	68
71	Physician Attitudes toward Adopting Genome-Guided Prescribing through Clinical Decision Support. Journal of Personalized Medicine, 2014, 4, 35-49.	2.5	43
72	Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process. Current Drug Metabolism, 2014, 15, 209-217.	1.2	341

#	Article	IF	Citations
73	Implementing Clinical Pharmacogenetics: Point-of-Care and Pre-Emptive Testing. , 2014, , 921-930.		0
74	Implementation and utilization of genetic testing in personalized medicine. Pharmacogenomics and Personalized Medicine, 2014, 7, 227.	0.7	63
75	Pharmacogenetics in Jewish populations. Drug Metabolism and Drug Interactions, 2014, 29, 221-233.	0.3	14
76	An Ashkenazi Jewish SMN1 haplotype specific to duplication alleles improves pan-ethnic carrier screening for spinal muscular atrophy. Genetics in Medicine, 2014, 16, 149-156.	2.4	64
77	Antiplatelet drug interactions with proton pump inhibitors. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 175-189.	3.3	35
78	CYP2C9 Allelic Variants and Frequencies in a Pediatric Sickle Cell Disease Cohort: Implications for NSAIDs Pharmacotherapy. Clinical and Translational Science, 2014, 7, 396-401.	3.1	8
79	Warfarin pharmacogenetic trials: is there a future for pharmacogenetic-guided dosing?. Pharmacogenomics, 2014, 15, 719-722.	1.3	23
80	Paroxysmal kinesigenic dyskinesia caused by 16p11.2 microdeletion. Tremor and Other Hyperkinetic Movements, 2014, 4, 274.	2.0	8
81	Warfarin pharmacogenetics: A controlled doseâ€“response study in healthy subjects. Vascular Medicine, 2013, 18, 290-297.	1.5	7
82	An Allele-Specific PCR System for Rapid Detection and Discrimination of the CYP2C19âˆ—4A, âˆ—4B, and âˆ—17 Alleles. Journal of Molecular Diagnostics, 2013, 15, 783-789.	2.8	17
83	Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet, The, 2013, 382, 790-796.	13.7	237
84	Clinical Pharmacogenomics: Opportunities and Challenges at Point of Care. Clinical Pharmacology and Therapeutics, 2013, 93, 33-35.	4.7	39
85	Frequency of the cholesteryl ester storage disease commonLIPAE8SJM mutation (c.894G>A) in various racial and ethnic groups. Hepatology, 2013, 58, 958-965.	7.3	85
86	Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity. Thrombosis and Haemostasis, 2013, 110, 118-123.	3.4	35
87	Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness. Pharmacogenomics Journal, 2012, 12, 297-305.	2.0	40
88	PharmGKB summary. Pharmacogenetics and Genomics, 2012, 22, 159-165.	1.5	141
89	Copy number variation and warfarin dosing: evaluation ofCYP2C9,VKORC1,CYP4F2,GGCXandCALU. Pharmacogenomics, 2012, 13, 297-307.	1.3	13
90	Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation. Journal of Hematology and Oncology, 2012, 5, 23.	17.0	21

#	Article	IF	Citations
91	Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy. Genetics in Medicine, 2012, 14, 990-1000.	2.4	39
92	Personalizing medicine with clinical pharmacogenetics. Genetics in Medicine, 2011, 13, 987-995.	2.4	173
93	Increased frequency of the glucocorticoid receptor A3669G (rs6198) polymorphism in patients with Diamond-Blackfan anemia. Blood, 2011, 118, 473-474.	1.4	13
94	CYP2C19 But Not PON1 Genetic Variants Influence Clopidogrel Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy in Postâ€“Myocardial Infarction Patients. Circulation: Cardiovascular Interventions, 2011, 4, 422-428.	3.9	110
95	Clinical, Angiographic, and Genetic Factors Associated With Early Coronary Stent Thrombosis. JAMA - Journal of the American Medical Association, 2011, 306, 1765-74.	7.4	179
96	Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases. Human Mutation, 2010, 31, 1240-1250.	2.5	125
97	Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. Journal of Thrombosis and Haemostasis, 2010, 8, 1018-26.	3.8	57
98	Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics, 2010, 11, 781-791.	1.3	146
99	Large inverted repeats within Xp11.2 are present at the breakpoints of isodicentric X chromosomes in Turner syndrome. Human Molecular Genetics, 2010, 19, 3383-3393.	2.9	28
100	Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. Journal of Human Genetics, 2010, 55, 731-737.	2.3	147
101	Detection of low-level mosaicism and placental mosaicism by oligonucleotide array comparative genomic hybridization. Genetics in Medicine, 2010, 12, 85-92.	2.4	78
102	Dasatinib Cerebrospinal Fluid Concentration and Plasma Pharmacokinetics: Potential for Central Nervous System Prophylaxis In Philadelphia Chromosome-Positive Leukemia. Blood, 2010, 116, 1807-1807.	1.4	2
103	CYP2C9*8is prevalent among Africanâ€“Americans: implications for pharmacogenetic dosing. Pharmacogenomics, 2009, 10, 1243-1255.	1.3	100
104	ABCG2 C.421C>A Is Associated with Higher Trough Imatinib Plasma Levels in Patients with Chronic Myeloid Leukemia.. Blood, 2009, 114, 110-110.	1.4	0
105	Warfarin Pharmacogenetics: CYP2C9 and VKORC1 Genotypes Predict Different Sensitivity and Resistance Frequencies in the Ashkenazi and Sephardi Jewish Populations. American Journal of Human Genetics, 2008, 82, 495-500.	6.2	122
106	Itraconazole Oral Solution Enhanced Vincristine Neurotoxicity in Five Patients with Malignant Lymphoma. Internal Medicine, 2008, 47, 651-653.	0.7	24
107	Molecular Medical Genetics. , 2008, , 417-440.		0
108	CYP2C9,CYP2C19andCYP2D6allele frequencies in the Ashkenazi Jewish population. Pharmacogenomics, 2007, 8, 721-730.	1.3	43

#	Article	IF	Citations
109	Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression. Experimental Hematology, 2007, 35, 263-273.	0.4	69
110	Decreased Expression of the Histone Methyltransferase SUV39H1 in AML Cells Reactivates Hypermethylated Tumor Suppressor p15INK4B in the Absence of Promoter Demethylation.. Blood, 2007, 110, 4150-4150.	1.4	0
111	5-Aza-2â€²-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation. Leukemia Research, 2006, 30, 69-76.	0.8	44
112	Methylation status of cyclin-dependent kinase inhibitor genes within the transforming growth factor beta pathway in human T-cell lymphoblastic lymphoma/leukemia. Leukemia Research, 2004, 28, 1293-1301.	0.8	12
113	Microsatellite mutations of transforming growth factor-Î² receptor type II and caspase-5 occur in human precursor T-cell lymphoblastic lymphomas/leukemias in vivo but are not associated with hMSH2 or hMLH1 promoter methylation. Leukemia Research, 2003, 27, 23-34.	0.8	21
114	MSH2-deficient murine lymphomas harbor insertion/deletion mutations in the transforming growth factor beta receptor type 2 gene and display low not high frequency microsatellite instability. Blood, 2000, 95, 1767-1772.	1.4	22